Syndax Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer therapies. Its products include candidate and entinostat. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SNDX
Previous Symbol
CUSIPN/A
Phone781-419-1400
Debt
Debt-to-Equity RatioN/A
Current Ratio5.63
Quick Ratio5.63
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.11 million
Price / Sales57.80
Cash FlowN/A
Price / Cash FlowN/A
Book Value$4.28 per share
Price / Book1.15
Profitability
EPS (Most Recent Fiscal Year)($2.90)
Net Income$-60,800,000.00
Net Margins-3,185.75%
Return on Equity-91.11%
Return on Assets-64.69%
Miscellaneous
Employees44
Outstanding Shares24,840,000
Market Cap$121.94 million
OptionableOptionable
Syndax Pharmaceuticals (NASDAQ:SNDX) Frequently Asked Questions
What is Syndax Pharmaceuticals' stock symbol?
Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX."
How were Syndax Pharmaceuticals' earnings last quarter?
Syndax Pharmaceuticals Inc (NASDAQ:SNDX) posted its quarterly earnings data on Monday, November, 5th. The company reported ($0.68) EPS for the quarter, beating the Zacks' consensus estimate of ($0.76) by $0.08. The company had revenue of $0.38 million for the quarter, compared to analyst estimates of $0.38 million. Syndax Pharmaceuticals had a negative net margin of 3,185.75% and a negative return on equity of 91.11%. View Syndax Pharmaceuticals' Earnings History.
When is Syndax Pharmaceuticals' next earnings date?
What price target have analysts set for SNDX?
4 brokers have issued 12-month target prices for Syndax Pharmaceuticals' stock. Their forecasts range from $6.00 to $40.00. On average, they anticipate Syndax Pharmaceuticals' stock price to reach $20.25 in the next year. This suggests a possible upside of 312.4% from the stock's current price. View Analyst Price Targets for Syndax Pharmaceuticals.
What is the consensus analysts' recommendation for Syndax Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syndax Pharmaceuticals.
What are Wall Street analysts saying about Syndax Pharmaceuticals stock?
Here are some recent quotes from research analysts about Syndax Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253 which are in clinical trial stage. Syndax Pharmaceuticals, Inc. is based in WALTHAM, United States. " (12/15/2018)
- 2. HC Wainwright analysts commented, "Valuation: We base our $30 price target on probability-adjusted revenue forecasts for entinostat in combination with other drugs in advanced HR+, HER2- breast cancer, NSCLC, and metastatic melanoma. We use the net present value of our revenue forecast through 2027, apply a 35% POS for HR+, HER2- breast cancer, and 10% POS for NSCLC and melanoma, with a 3x price/sales multiple, and we value the early stage pipeline at $10 million, the amount of the upfront payments the company made to acquire the menin inhibitors and SNDX-6352, to arrive at our price target." (7/12/2018)
Has Syndax Pharmaceuticals been receiving favorable news coverage?
Headlines about SNDX stock have trended somewhat positive recently, InfoTrie Sentiment reports. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Syndax Pharmaceuticals earned a news sentiment score of 1.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
Who are some of Syndax Pharmaceuticals' key competitors?
Some companies that are related to Syndax Pharmaceuticals include Zymeworks (ZYME), Prothena (PRTA), Epizyme (EPZM), Corium International (CORI), Arvinas (ARVN), Beyondspring (BYSI), Rigel Pharmaceuticals (RIGL), BioSpecifics Technologies (BSTC), GlycoMimetics (GLYC), Akebia Therapeutics (AKBA), Achillion Pharmaceuticals (ACHN), Xeris Pharmaceuticals (XERS), Cytokinetics (CYTK), Dova Pharmaceuticals (DOVA) and Dermira (DERM).
Who are Syndax Pharmaceuticals' key executives?
Syndax Pharmaceuticals' management team includes the folowing people:
- Briggs W. Morrison, Chief Executive Officer & Director
- Michael A. Metzger, President & Chief Operating Officer
- Richard P. Shea, Chief Financial Officer & Treasurer
- Peter Ordentlich, Chief Scientific Officer
- Michael L. Meyers, Chief Medical Officer & Senior Vice President
When did Syndax Pharmaceuticals IPO?
(SNDX) raised $66 million in an IPO on Thursday, March 3rd 2016. The company issued 4,400,000 shares at $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.
Who are Syndax Pharmaceuticals' major shareholders?
Syndax Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.08%), Dimensional Fund Advisors LP (3.20%), Vanguard Group Inc (2.97%), Vanguard Group Inc. (2.97%), FMR LLC (1.40%) and Renaissance Technologies LLC (1.12%). View Institutional Ownership Trends for Syndax Pharmaceuticals.
Which major investors are selling Syndax Pharmaceuticals stock?
Which major investors are buying Syndax Pharmaceuticals stock?
SNDX stock was acquired by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Renaissance Technologies LLC, Point72 Asset Management L.P., BlackRock Inc., Sofinnova Ventures Inc, Panagora Asset Management Inc., Bridgeway Capital Management Inc. and Morgan Stanley. View Insider Buying and Selling for Syndax Pharmaceuticals.
How do I buy shares of Syndax Pharmaceuticals?
Shares of SNDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Syndax Pharmaceuticals' stock price today?
One share of SNDX stock can currently be purchased for approximately $4.91.
How big of a company is Syndax Pharmaceuticals?
Syndax Pharmaceuticals has a market capitalization of $121.94 million and generates $2.11 million in revenue each year. The company earns $-60,800,000.00 in net income (profit) each year or ($2.90) on an earnings per share basis. Syndax Pharmaceuticals employs 44 workers across the globe.
What is Syndax Pharmaceuticals' official website?
How can I contact Syndax Pharmaceuticals?
Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The company can be reached via phone at 781-419-1400 or via email at [email protected]
MarketBeat Community Rating for Syndax Pharmaceuticals (NASDAQ SNDX)
MarketBeat's community ratings are surveys of what our community members think about Syndax Pharmaceuticals and other stocks. Vote "Outperform" if you believe SNDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
